Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

New anticancer agents in clinical development

J Eckardt¹, G Eckhardt, M Villalona-Calero

¹Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas, USA.

Oncology (Williston Park, N.Y.)

|November 1, 1995

Summary

New cancer treatments are being developed, including novel antineoplastic compounds and agents that alter the cancer cell phenotype. These innovative therapies target key cellular processes for improved patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

Clinically decisive (dis)agreement in multidisciplinary team assessment of esophageal squamous cell carcinoma; a prospective, national, multicenter study.

Acta oncologica (Stockholm, Sweden)·2021

Same author

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Same author

Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias.

Investigational new drugs·2014

Same author

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.

Cancer chemotherapy and pharmacology·2013

Same author

Population screening for the mutation associated with osteogenesis imperfecta in dachshunds.

The Veterinary record·2013

Area of Science:

Oncology
Biochemistry
Pharmacology

Background:

Advances in understanding cancer cell biology and biochemistry have spurred the development of novel antineoplastic compounds.
Current research focuses on drugs targeting critical cellular pathways and agents that modify the cancer cell phenotype.

Purpose of the Study:

To review promising new antineoplastic compounds and phenotypic-altering agents in clinical development.
To highlight the diverse strategies being explored for more effective cancer treatment.

Main Methods:

Review of ongoing phase I, II, and III clinical trials for new cancer therapeutics.
Categorization of novel agents based on their mechanism of action, including topoisomerase I inhibitors, antimetabolites, and phenotypic modulators.

Related Experiment Videos

Main Results:

Several classes of antineoplastic compounds are in advanced clinical testing, including camptothecin analogs (9-aminocamptothecin, irinotecan, topotecan), docetaxel, gemcitabine, and thymidylate synthase (TS) inhibitors.
Emerging therapeutic strategies involve agents that induce a less malignant state, such as angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.

Conclusions:

A deeper understanding of cancer biology is driving the development of targeted therapies.
Multiple promising avenues, from direct cytotoxic agents to phenotype-modifying strategies, are advancing cancer treatment research.